Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 批发和零售业
Company Introduction 国药集团一致药业股份有限公司是集制药工业、医药批发、零售连锁为一体的医药上市公司,控股股东为国药控股有限公司.主要经营医药企业受托管理、资产重组,医药实业投资项目的咨询服务,举办医疗器械的展览展销,中药材、中成药、中药饮片、化学原料药、化学药制剂、抗生素、生化药品、生物制品的批发(经营期限以许可证为准).公司坚持走研发、制药、分销、物流、零售一体化发展道路,旗下拥有致君制药、万乐公司、一致药店等公司,其中一致药店为国内最大规模的连锁药店之一.公司为国药控股在中国南区的医药分销、物流、生产、研发和投资中心公司,还承担深圳市政府的国家药品储备任务,并享有麻醉药品经营权及甘草、麻黄草专营权。
Main Business 药品的研发、生产，中西成药、中药材、生物制品、生化药品、保健品、医疗器械的批发销售和连锁零售。
Legal Representative 吴壹建
Top Executives
董事长：吴壹建
董事：罗娴,李进雄,吴壹建
独立董事：李洪海,毕亚林,江百灵,苏薇薇
Top 5 Shareholder
Shareholder name Nature Holding Date
国药控股股份有限公司限售股+流通A股56.06%30/09/2024
中国工商银行股份有限公司－东方红启恒三年持有期混合型证券投资基金流通A股2.65%30/09/2024
中国工商银行股份有限公司－东方红睿玺三年持有期混合型证券投资基金流通A股1.67%30/09/2024
全国社保基金四一三组合流通A股1.36%30/09/2024
中国医药对外贸易有限公司流通A股1.24%30/09/2024
Company Secretary 李川
Solicitors 国浩律师（上海）事务所
Auditors 普华永道中天会计师事务所（特殊普通合伙）;天职国际会计师事务所（特殊普通合伙）
Tel No 0755-25875152;0755-25875222
Fax No 0755-25195435
Website www.szaccord.com.cn
Email gyyz0028@sinopharm.com；gyyzinvestor@sinopharm.com
Company Address
Register: 广东省深圳市福田区八卦四路15号一致药业大厦
Office: 广东省深圳市福田区八卦四路15号一致药业大厦
Listing Date 09/08/1993
Shares Capital
Shares Capital: 556,565,077
Total A Share: 485,215,260
Listed A Share: 478,053,713
Non-tradable A Share: 7,161,547
Other Share: 0
Total B Share: 71,349,817
Total H Share: 0
EPS(RMB)* ¥ 2.870
DPS(RMB)* ¥ 0.680
NBV Per Share(RMB)* ¥ 31.290
Market Capitalization(RMB) 14.557B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.